Descrizione

The microbiome is the natural bacterial colonisation of the body – including skin, gut and stomach. The human microbiome refers to the spectrum of microbes (microbiota) that colonize humans. Microbiome therapies are currently focused on the prevention of C. difficile recurrence. This bacterium is often contracted in hospitals following antibiotic administration or a period of immunosuppression. The global microbiome therapeutics market is set to grow by US$ 918 milioni durante 2021-2027, crescendo ad un tasso di crescita annuale composto (CAGR) Di 32.5% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix. Significant external funding for executing research and therapeutic innovation, increasing adoption of inorganic growth strategies in the market, growing demand for novel therapies to address the unmet needs of many diseases are expected to boost the market growth in the coming years.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for microbiome therapeutics. The global microbiome therapeutics market is segmented on the basis of target therapy area, regione. By target therapy area, it is categorized into gastrointestinal diseases, infections, e altri. The gastrointestinal diseases segment held the largest market share in 2020. By region, the microbiome therapeutics market is divided into North America, Asia Pacifico, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as 4D Pharma plc, AOBiome Therapeutics Inc., Assembly Biosciences Inc., Eligo Bioscience S.A.S, Finch Therapeutics Group Inc., MaaT Pharma SA, Quorum Innovations LLC, Rebiotix Inc. (Ferring Pharmaceuticals Group), Seres Therapeutics Inc., Synthetic Biologics, Vedanta Biosciences Inc..

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the microbiome therapeutics market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Target therapy area: gastrointestinal diseases, infections, e altri
Regione: Nord America, Asia Pacifico, Europa, and Rest of the World (ROW)
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

Get a comprehensive picture of the global microbiome therapeutics market
Individuare i settori in crescita e le tendenze per gli investimenti
Understand what the future of the global microbiome therapeutics market looks like
Identificare il panorama competitivo e la finestra di opportunità

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato & Veduta
3.1 Valore di mercato
3.2 Previsione del valore di mercato
4. Microbiome Therapeutics Market by Target Therapy Area
4.1 Gastrointestinal Diseases
4.2 Infections
4.3 Altri
5. Microbiome Therapeutics Market by Region
5.1 Nord America
5.2 Asia Pacifico
5.3 Europa
5.4 Rest Of The World (Row)
6. Profili aziendali
6.1 4D Pharma plc
6.2 AOBiome Therapeutics, Inc.
6.3 Assembly Biosciences, Inc.
6.4 Eligo Bioscience S.A.S
6.5 Finch Therapeutics Group, Inc.
6.6 MaaT Pharma SA
6.7 Quorum Innovations, LLC
6.8 Rebiotix, Inc. (Ferring Pharmaceuticals Group)
6.9 Seres Therapeutics, Inc.
6.10 Synthetic Biologics
6.11 Vedanta Biosciences, Inc.
7. Appendice
7.1 Informazioni su StrategyHelix
7.2 Disclaimer